JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

Strona główna・Stock List・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Closed

SectorHealthcare

7.35 0.68

Buy Sell

Overview

Share price change

24h

Current

Min

7.16

Max

7.38

Key metrics
By Trading Economics
Income	5.7M -30M
Sales	3.1M 34M
Profit margin	-89.424
Employees	182
EBITDA	5.2M -35M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+219.57% upside

Dividends
By Dow Jones
Next Earnings	4 lis 2025

Market Stats
By TradingEconomics
Market Cap	76M 759M
Previous open	6.67
Previous close	7.35

News Sentiment

By Acuity

50%

163 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

6.26 / 7.47 Support & Resistance

Day One Biopharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 paź 2025, 20:49 UTC

Earnings

Correction to Thermo Fisher Article on Oct. 22

23 paź 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 paź 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 paź 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 paź 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 paź 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 paź 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 paź 2025, 22:49 UTC

Acquisitions, Mergers, Takeovers

How Trump Sparked a New Era of State Capitalism -2-

23 paź 2025, 22:49 UTC

Acquisitions, Mergers, Takeovers

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 paź 2025, 22:17 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 paź 2025, 21:41 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 paź 2025, 21:05 UTC

Earnings

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 paź 2025, 20:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

23 paź 2025, 20:50 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

23 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 paź 2025, 20:35 UTC

Earnings

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 paź 2025, 20:28 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 paź 2025, 20:15 UTC

Market Talk

Earnings

Global Commodities Roundup: Market Talk

23 paź 2025, 20:10 UTC

Earnings

Newmont Mining 3Q Adj EPS $1.71

23 paź 2025, 20:10 UTC

Earnings

Newmont Mining 3Q Sales $5.52B

23 paź 2025, 20:10 UTC

Earnings

Newmont Mining 3Q EPS $1.67

23 paź 2025, 20:09 UTC

Earnings

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 paź 2025, 20:07 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

23 paź 2025, 20:07 UTC

Market Talk

Earnings

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 paź 2025, 20:07 UTC

Earnings

Blackstone Looks to IPOs for Investment Exits -- Update

23 paź 2025, 20:05 UTC

Earnings

Intel 3Q Gross Margin 38.2% >INTC

23 paź 2025, 20:04 UTC

Earnings

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 paź 2025, 20:04 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 paź 2025, 20:04 UTC

Earnings

Intel: 4Q Guidance Excludes Altera >INTC

23 paź 2025, 20:04 UTC

Earnings

Intel Sees 4Q Adj EPS 8c >INTC

Peer Comparison

Price change

Day One Biopharmaceuticals Inc Forecast

Price Target

By TipRanks

230.58% upside

12 Months Forecast

Average 24 USD 230.58%

High 34 USD

Low 16 USD

Based on 9 Wall Street analysts offering 12 month price targets forDay One Biopharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Day One Biopharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

6.26 / 7.47Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

163 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.